Status:
COMPLETED
Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
Safety, tolerability and pharmacokinetics of single and multiple oral doses of BI 409306 tablets in healthy Chinese and Japanese male volunteers of a known genotype as specified in the study protocol.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy male Chinese and Japanese volunteers
- Age between 20 and 45 years
- BMI between 18.5 and 25 kg/m2 (Body Mass Index)
- Known genotype as specified in the study protocol
- Subjects must be able to understand and comply with study requirements
- Exclusion criteria:
- 1\. Any deviation from healthy condition
Exclusion
Key Trial Info
Start Date :
April 22 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 2013
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01841112
Start Date
April 22 2013
End Date
July 18 2013
Last Update
June 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1289.4.8201 Boehringer Ingelheim Investigational Site
Seoul, South Korea